Zobrazeno 1 - 10
of 3 539
pro vyhledávání: '"A J Korman"'
Autor:
Jason R Baird, Alejandro F Alice, Roland Saito, Qingqing Chai, Minhua Han, Cindy Ng, Stephanie Han, Beth Fernandez, Sarah Ledoux, Johannes Grosse, Alan J Korman, Megan Potuznik, Venkatesh Rajamanickam, Brady Bernard, Marka R Crittenden, Michael J Gough
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-17 (2024)
Abstract The uniqueness in each person’s cancer cells and variation in immune infiltrates means that each tumor represents a unique problem, but therapeutic targets can be found among their shared features. Radiation therapy alters the interaction
Externí odkaz:
https://doaj.org/article/cbaeda0ee181438bbb8d05f9ec45b660
Autor:
Richard B. Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J. Korman, Yu-Huei Huang, Georgios Kokolakis, Andreas Pinter, Nadia Ibrahim, Yanbing Zheng, Leonidas Drogaris, Vassilis Stakias, Ahmed M. Soliman, Simone Rubant, Diamant Thaçi
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 12, Pp 3273-3290 (2024)
Abstract Introduction Risankizumab has demonstrated superior efficacy compared to other psoriasis treatments, including secukinumab, adalimumab, and ustekinumab; switching to risankizumab from other psoriasis treatments has shown superior clinical an
Externí odkaz:
https://doaj.org/article/34355c7facb14d3c80d5e8afaa8abaab
Autor:
Neil J. Korman, Richard B. Warren, Jerry Bagel, April W. Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Andrew Blauvelt
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Aim: In the global phase 3 POETYK PSO-1 and PSO-2 trials, significantly greater proportions of deucravacitinib-treated patients met the coprimary endpoints (PASI 75, sPGA 0/1) at Week 16 versus placebo or apremilast-treated patients. This analysis ev
Externí odkaz:
https://doaj.org/article/565ff6e9db3f40f3996833c3bba76026
Autor:
Joshua Burshtein, Milaan Shah, Danny Zakria, Benjamin Lockshin, Jeff Crowley, Joseph F. Merola, Ken Gordon, Mona Shahriari, Neil J. Korman, Raj Chovatiya, Robert Kalb, Mark Lebwohl
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 2, Pp 323-339 (2024)
Abstract Introduction Psoriasis is a chronic inflammatory condition affecting the skin, joints, and several other organ systems with significant disease burden. Bimekizumab is the first monoclonal antibody targeting both interleukin (IL)-17A and inte
Externí odkaz:
https://doaj.org/article/5d0a3eb8c3af4834a758e9dc334fd9fd
Autor:
Susan Taylor, Neil J. Korman, Tsen-Fang Tsai, Yutaka Shimomura, Meghan Feely, Yves Dutronc, Wen-Shuo Wu, Najwa Somani, Antonella Tosti
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 12, Pp 3181-3191 (2023)
Abstract Background Baricitinib, an oral selective JAK1/JAK2 inhibitor, is approved for the treatment of adults with severe alopecia areata (AA). Objective To evaluate differences in response up to week 52 among subgroups based on the baseline severi
Externí odkaz:
https://doaj.org/article/ec3994a4004f469cadd3311b93a0b34b
Autor:
Phuong Daniels, DPT, Yujie Linda Liou, DO, Kelly B. Scarberry, MD, Timmie R. Sharma, MD, Neil J. Korman, MD, PhD
Publikováno v:
JAAD Case Reports, Vol 35, Iss , Pp 103-107 (2023)
Externí odkaz:
https://doaj.org/article/2afd7232a370461f895f7e16935ddf90
Publikováno v:
Nishi Nihon Hifuka. 78:71-72
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::401405511d7176fd7812c4699977a6d7
https://doi.org/10.2336/nishinihonhifu.78.71
https://doi.org/10.2336/nishinihonhifu.78.71
Autor:
Marine Guignant, Billal Tedbirt, Dedee F. Murrell, Masayuki Amagai, Valeria Aoki, Johannes Bauer, Giuseppe Ciancinni, Donna Culton, Maryam Daneshpazhooh, Dipankar De, Janet Fairley, Russell Hall, Soo-Chan Kim, Neil J. Korman, Cezary Kowalewski, Daniel Mimouni, Aikaterini Patsatsi, Vivien Hebert, Marwah Adly Mohamed Saleh, Enno Schmidt, Eli Sprecher, Soner Uzun, Vanessa Venning, Victoria P. Werth, Detlef Zillikens, Pascal Joly
Publikováno v:
JID Innovations, Vol 2, Iss 4, Pp 100129- (2022)
Many treatments are currently proposed for treating patients with bullous pemphigoid (BP). We assessed treatment modalities of BP depending on the different countries, BP extent, and patients’ comorbidities. We surveyed worldwide experts about how
Externí odkaz:
https://doaj.org/article/c328540373d141a09e5d3b87c5cd958e
Autor:
Ornella Pagliano, Robert M. Morrison, Joe-Marc Chauvin, Hridesh Banerjee, Diwakar Davar, Quanquan Ding, Tokiyoshi Tanegashima, Wentao Gao, Saranya R. Chakka, Richelle DeBlasio, Ava Lowin, Kevin Kara, Mignane Ka, Bochra Zidi, Rada Amin, Itay Raphael, Shuowen Zhang, Simon C. Watkins, Cindy Sander, John M. Kirkwood, Marcus Bosenberg, Ana C. Anderson, Vijay K. Kuchroo, Lawrence P. Kane, Alan J. Korman, Arvind Rajpal, Sean M. West, Minhua Han, Christine Bee, Xiaodi Deng, Xiao Min Schebye, Pavel Strop, Hassane M. Zarour
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 9 (2022)
T cell immunoglobulin mucin domain-containing protein 3 (Tim-3) negatively regulates innate and adaptive immunity in cancer. To identify the mechanisms of Tim-3 in cancer immunity, we evaluated the effects of Tim-3 blockade in human and mouse melanom
Externí odkaz:
https://doaj.org/article/00341078d5a94f57ba93043742d00efb
Autor:
Sonja Ständer, MD, Matthias Augustin, MD, Tim Berger, MD, Sarina Elmariah, MD, Neil J. Korman, MD, Elke Weisshaar, MD, Gil Yosipovitch, MD
Publikováno v:
JAAD International, Vol 2, Iss , Pp 28-30 (2021)
Externí odkaz:
https://doaj.org/article/298ed91f9d7342f98379f472f1c2365b